<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066335</url>
  </required_header>
  <id_info>
    <org_study_id>DPM401</org_study_id>
    <nct_id>NCT04066335</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Nanoxel M Inj.</brief_title>
  <official_title>An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety of Nanoxel M inj. administration in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective observational study to observe the incidence of adverse
      events under actual clinical settings to test the safety of Nanoxel-M inj. administration in
      patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer,
      head &amp; neck cancer, gastric cancer or esophageal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Nanoxel M inj.</measure>
    <time_frame>through study completion, an average of 6cycles(each cycle is 3weeks)</time_frame>
    <description>The incidence of Treatment-Emergent Adverse Event</description>
  </primary_outcome>
  <enrollment type="Anticipated">1498</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are assessed as adequate to administer Nanoxel M inj.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults â‰¥18 years old

          2. Patients who have signed written consent form prior to participating in the clinical
             trial

          3. Patients who are assessed as adequate to administer Nanoxel M injection.

        Exclusion Criteria:

        1) Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samyang Biopharmaceuticals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi-ryung Jin</last_name>
      <phone>82-2-2157-9841</phone>
      <email>miryung.jin@samyang.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Observational Study, Safety, Nanoxel M, Docetaxel</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

